Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
CencoraWBO:ABC -1.67%72 Cash-to-Debt is 0.24 as of Jun. 2026, which is 57% below its 10-year median of 0.56. GuruFocus rates WBO:ABC with a GF Score™ of 72/100 and a GF Value™ of €259.58 (Fairly Valued). The stock has 2 warning signs investors should review. Among 121 Medical Distribution companies, Cencora ranks worse than 68.6% on this metric.
Cash to Debt Ratio measures the financial strength of a company. It is calculated as a company's cash, cash equivalents, and marketable securities divide by its debt. Cencora's cash to debt ratio for the quarter that ended in Jun. 2026 was 0.24.
If Cash to Debt ratio is less than 1, the company cannot pay off its debt using the cash in hand. Here we can see, Cencoracouldn't pay off its debt using the cash in hand for the quarter that ended in Jun. 2026.
The historical rank and industry rank for Cencora's Cash-to-Debt or its related term are showing as below:
WBO:ABC'
s Cash-to-Debt Range Over the Past 10 Years
Min: 0.18 Med: 0.56 Max: 1.32
Current: 0.24
During the past 13 years, Cencora's highest Cash to Debt Ratio was 1.32. The lowest was 0.18. And the median was 0.56.
WBO:ABC's Cash-to-Debt is ranked worse than 68.6% of 121
companies
in the Medical Distribution industry
Industry Median: 0.59
vs WBO:ABC: 0.24
If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. If it is smaller than 1, it means the company has more debt than the cash in hands. In this case, it is important to look the the company's Interest Coverage. Ben Graham requires that a company must have an Interest Coverage of at least 5.
Cencora Cash-to-Debt Related Terms
Cencora Cash-to-Debt Historical Data
* Premium members only.
The historical data trend for Cencora's Cash-to-Debt can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Note: An indication of "No Debt" does not necessarily mean that the company has no debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.
WBO:ABC vs CAH, MCK, HSIC: Cash-to-Debt Comparison
For the Medical Distribution subindustry, Cencora's Cash-to-Debt, along with its competitors' market caps and Cash-to-Debt data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Cencora Cash-to-Debt vs Medical Distribution Industry
For the Medical Distribution industry and Healthcare sector, Cencora's Cash-to-Debt distribution charts can be found below:
* The bar in red indicates where Cencora's Cash-to-Debt falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Cencora (WBO:ABC) has a Cash-to-Debt of 0.24 as of Jun. 2026. This is 57% below median its historical median of 0.56. Over the past decade, Cencora's Cash-to-Debt has ranged from 0.18 to 1.32. According to the industry distribution chart, Cencora ranks #83 out of 121 companies in the Medical Distribution industry, placing it in the top 68.6%.
Is Cencora's Cash-to-Debt too high?
Cencora's current Cash-to-Debt of 0.24 is 57% below median its 10-year median of 0.56. Over the past 10 years, this metric has ranged from a low of 0.18 to a high of 1.32. The Medical Distribution industry median Cash-to-Debt is 0.59. Cencora's value of 0.24 is 59.3% below this industry median. Based on the distribution chart, Cencora ranks #83 out of 121 companies in the Medical Distribution industry, which is below the industry midpoint. Overall, Cencora has a GF Score™ of 72/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Cencora's Cash-to-Debt compare to CAH and MCK?
According to the Medical Distribution industry distribution chart, Cencora ranks #83 out of 121 companies for Cash-to-Debt. This places Cencora in the lower half of its industry. The industry median Cash-to-Debt is 0.59. Cencora's value of 0.24 is 59.3% below this benchmark. Historically, Cencora's own Cash-to-Debt has ranged from 0.18 to 1.32 over the past decade. While the company's 10-year median is 0.56 vs. the industry median of 0.59, Cencora has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cash-to-Debt for a Medical Distribution company?
The median Cash-to-Debt among Medical Distribution companies is 0.59, based on 121 companies in the industry. Companies in the top quartile (top 25%) have a Cash-to-Debt significantly above this median, while those in the bottom quartile fall well below. However, Cash-to-Debt should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Cencora's current Cash-to-Debt of 0.24 is 59.3% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cash-to-Debt mean?
A high Cash-to-Debt can signal that a stock is expensive relative to its fundamentals. For the Medical Distribution industry, the median Cash-to-Debt is 0.59 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Cencora's current Cash-to-Debt is 0.24, which is 57% below median its own 10-year median of 0.56. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Cencora stock overvalued right now?
Based on GuruFocus' analysis, Cencora (WBO:ABC) is currently considered Fairly Valued. The stock's GF Value™ is €259.58, compared to a current price of €283.10 — trading 9.1% above its estimated fair value. The current Cash-to-Debt is 0.24, which is 57% below median its 10-year median of 0.56 and 59.3% below the Medical Distribution industry median of 0.59. Cencora's overall GF Score™ is 72/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cash-to-Debt calculated?
Cash-to-Debt is calculated from a company's financial statements. For Cencora (WBO:ABC), the current Cash-to-Debt is 0.24 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Cencora (WBO:ABC) Overvalued in 2026?
Based on GuruFocus' analysis, Cencora stock appears to be overvalued.
The current stock price of €283.10 is trading 9.1% above its estimated GF Value™ of €259.58.
GuruFocus considers Cencora to be Fairly Valued.
Key valuation signals for WBO:ABC:
Cash-to-Debt: 0.24 (57% below median its 10-year median of 0.56)
GF Value™: €259.58 vs. price of €283.10 (9.1% above fair value)
Industry Position: 59.3% below the Medical Distribution median (#83 of 121)
No single metric tells the full story. See the WBO:ABC stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Cencora is one of three leading domestic pharmaceutical wholesalers. It sources and distributes branded, generic, and specialty pharmaceutical products to pharmacies (retail chains, independent, and mail order), hospital networks, and healthcare providers. It and McKesson and Cardinal Health hold over 90% share of the US pharmaceutical wholesale industry. Cencora also provides commercialization services for manufacturers of pharmaceuticals and medical devices, global specialty drug logistics (World Courier), and animal health product distribution (MWI Animal Health). Cencora expanded its international presence in 2021 by purchasing Alliance Healthcare, one of the leading drug wholesalers in Europe.
72GF Score
Get the complete analysis for WBO:ABC
Cash-to-Debt is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
WBO:ABC has been successfully added to your 
